Evidence map›Paper›PMID 37584733›Full record

ArticleBiochemical genetics2024

Assessment of Ecotropic Viral Integration Site 2B (EVI2B) Gene in Juvenile Myelomonocytic Leukemia and Neurofibromatosis Type 1 NF1 Tumors.

Parisa Saharafi, İrem Akar, Sibel Ersoy-Evans, Banu Anlar, Ali Varan, Ibrahim Vargel, Mualla Cetin, Sukriye Ayter

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Parisa SaharafiDepartment of Medical Biology and Genetics, Faculty of Medicine, TOBB University of Economics and Technology, Ankara, Turkey.
İrem AkarCenter for Stem Cell Research and Development (PEDI-STEM), Hacettepe University, Ankara, Turkey.
Sibel Ersoy-EvansDepartment of Dermatology, School of Medicine, Hacettepe University, Ankara, Turkey.
Banu AnlarDepartment of Pediatrics, Pediatric Neurology, School of Medicine, Hacettepe University, Ankara, Turkey.
Ali VaranDepartment of Pediatrics, Pediatric Oncology, School of Medicine, Hacettepe University, Ankara, Turkey.
Ibrahim VargelDepartment of Plastic Reconstructive and Aesthetic Surgery, School of Medicine, Hacettepe University, Ankara, Turkey.
Mualla CetinSchool of Medicine, Department of Hematology, Hacettepe University, Ankara, Turkey.
Sukriye AyterDepartment of Medical Biology and Genetics, Faculty of Medicine, TOBB University of Economics and Technology, Ankara, Turkey. sayter@etu.edu.tr.
Hacettepe University · TRTOBB University of Economics and Technology · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease that affects the development and growth of various tissues. NF1 is a major risk factor for the development of malignancies, particularly malignant peripheral nerve sheath tumors, optic gliomas, and leukemia. NF1 encodes a neurofibromin. Three genes, EVI2A, EVI2B, and OMGP, are embedded within intron 27b of NF1. However, the function of these genes remains unclear. EVI2A and EVI2B encode for putative transmembrane proteins. Mouse homologs are associated with viral insertions involved in leukemia in mice. Mouse Evi2b has been identified as a direct target gene of C/EBPα, a transcription factor critical for myeloid differentiation. Also possible is that these genes are related to the leukemia observed in patients with NF1. These genes might act as modifiers of NF1 phenotypic variations. Therefore, we investigated the EVI2B gene in leukemia and NF1 tumors. We analyzed DNA from 10, 20, and 3 patients with NF1, leukemia, and NF1-leukemia, respectively, and six NF1 tumor tissues. DNA sequencing analysis was used to identify the viral integration sequence, and the protein amounts and EVI2B gene expression were analyzed by flow cytometry and quantitative real-time PCR techniques. The EVI2B gene expression was increased in cutaneous neurofibroma compared with the control both at the level of protein and mRNA. However, its expression in plexiform neurofibroma was decreased significantly at protein level and increased at mRNA level compare to control. Moreover, integration of 455 bases near the 3' end of the exon was detected. When this integrated sequence was blasted into the NCBI retroviral genome database, an 87% match with the HIV-1 virus envelope gene was obtained. These preliminary results show that EVI2B might be important in NF1 tumorigenesis and leukemia.

Indexed as

Leukemia, Myelomonocytic, JuvenileNeurofibromatosis 1AnimalsHumansMembrane GlycoproteinsMiceNeurofibromin 1RNA, MessengerVirus IntegrationEVI2B protein, humanMembrane GlycoproteinsNeurofibromin 1RNA, MessengerEVI2B geneModifier genesNeurofibromatosis Type 1Viral integration region

Identifiers

PMID37584733
OpenAlexW4385851021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.